EXC vs MRNA
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Nov 12, 2026
EXC
MRNA
Investment Advisor Scores
MRNA
AI Analyst Insights
Detailed Metrics Comparison
| Metric | EXC | MRNA | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 14.9254 | 23.0415 | EXC |
| PEG Ratio | 2.4472 | 0 | Tie |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 9.2% | 29.2% | MRNA |
| Earnings Growth | -18.6% | -85.1% | EXC |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 44.9/100 | 38.7/100 | EXC |
| Profit Margin | 10.2% | -110.5% | EXC |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | HOLD | AVOID NEW MONEY | EXC |
Relative Price Performance (Last 90 Days)
Current Technical Phase
EXC
NeutralMixed signals - no dominant trend phase, RSI 60
MRNA
MarkupPrice above SMA50, rising 50-day trend (32.0% over 20 days), RSI 53
Fundamentals Snapshot
| Metric | EXC | MRNA |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 15.1 | -53.3 |
| Trailing P/E | 17.8 | — |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.1% | 0.3% |
| Gross Margin | 0.4% | -0.4% |
| Operating Margin | 0.2% | -0.8% |
| EPS | 2.56 | -6.98 |
| Dividend Yield | 0.04% | — |